popular. The technical advancement of ECMO pumps and tubing, as well as the unfavourable results of the SHOCK II trial for the use of the intraaortic ballon pump in cardiogenic shock [2] have led to a broader application of vaECMO. In postcardiotomy syndrome, vaECMO therapy is associated with rather poor results due to the critical myocardial damage during cardiac surgery [3] . The management of ECMO is still challenging and should be reserved for experienced interdisciplinary teams, consisting of cardiac surgeons, intensivists and cardiologists. N onphysician personnel, such as perfusionists and intensive care nurses, are also of crucial importance for the successful management of patients on ECMO. This report focuses on vaECMO for acute cardiogenic shock. It outlines the intention to treat of ECMO, technical aspects and outcome with respect to survival and complications, while it t akes i nto consideration the particular c ircumstances of cardiogenic shock.
The state of cardiogenic shock
Cardiogenic shock is far more than loss of cardiac contractility with subsequent low output syndrome. It is a complex, degenerating clinical downward spiral of multiorgan dysfunction that begins when the heart is no longer able to provide sufficient flow to the peripheral organs [14] . Hypotension, systemic hypoperfusion and end-organ ischaemia follow. Compensatory vasoconstriction is insufficient, at least in part because of the developing s ystemic inflammatory response syndrome (SIRS). Proinflammatory cytokines such as inter leukin (IL)-1β, IL-6, IL-8, tumour necrosis factor-α (TNF-α), as well as C-reactive protein, soluble adhesion molecules, leucocytes and the complement system are Introduction Extracorporeal m embrane oxygenation ( ECMO) is established as veno-venous ECMO (vvECMO) for respiratory failure and as veno-arterial ECMO (vaECMO) for cardiogenic shock which may result from acute or acute-on-chronic heart failure and from postcardiotomy syndrome subsequent to cardiac surgery. Therapy with ECMO has been steadily increasing over the past few years. This is mainly due to its application as vvECMO in respiratory failure, particularly acute respiratory distress syndrome (ARDS). Since the CESAR trial documented a survival and quality-of-life benefit for ARDS patients treated with vvECMO as compared CARDIOVASCULAR MEDICINE -KARDIOVASKULÄRE MEDIZIN -MÉDECINE CARDIOVASCULAIRE 2016; 19 (2): [39] [40] [41] [42] [43] mation [15, 17] . The effects of proinflammatory cytokines are mediated, to a large extent, through upregulation of nitric oxide (NO) production. Excessive NO d ecreases m yocardial contractility, s uppresses mito chondrial respiration, reduces the responsiveness to catecholamines and, thus, inhibits the positive inotropic response and induces inappropriate systemic vasodilation, leading to generalised hypoperfusion of peripheral organs [14, 15] . High levels of NO are generated by induction of inducible nitric oxide synthase (iNOS), which is expressed in rather small amounts under physiological conditions and is upregulated in inflammatory states [15, 18] . Inhibition of the iNOS, however, could not be shown to improve outcome in cardiogenic shock. The randomised multicentre TRIUMPH trial, designed to test the effect of NOS inhibition on mortality in patients with persistent cardiogenic shock complicating myocardial infarction, did not detect a difference in 30-day and 6-month mortality between patients who received the nonselective NOS inhibitor tilarginine and those who received placebo [15, 19] . The main reason for the failure of NOS inhibition to improve outcome in cardiogenic shock might be t hat a nonselective NOS inhibition was applied, which also inhibited the two other NOS isoforms, endothelial (eNOS) and neuronal (nNOS) and, thereby, adversely affected the protective actions of constitutively generated NO [15] . In septic shock, nonselective NOS inhibition has been shown to even increase m ortality [ 20] . O ther t rials examining the effects of various mediator-specific anti-inflammatory agents in septic shock, directed against TNF-α, IL-1, platelet activating factor, and others, were not able either to demonstrate an improvement in outcome [15, 21] . More general, nonspecific anti-inflammatory treatment of septic s hock w ith low-dose s teroids achieved, in contrast to high dosage, beneficial effects on survival, presumably since low steroid doses still attenuate the deleterious effects of systemic inflammation, while they do not eliminate the favourable actions of low-grade cytokine activation [15, 22] . This concept might be a way to improve outcome also in cardiogenic shock. The restoration of cardiac output via ECMO is intended to reverse this inflammatory cascade.
ECMO treatment strategies
Veno-arterial ECMO for cardiogenic shock is implanted in an emergency situation. There is not much time to make a decision about which therapeutic approach will follow ECMO. Potential comorbidities and the psychosocial environment cannot be evaluated, but this is a precondition before a therapeutic concept can be elaborated. Therefore, ECMO is implanted as a bridge to decision to make time for further evaluation. Once the investigations are completed, one of the following four options may be chosen for the ensuing treatment short-term mechanical circulatory support may be considered as a "bridge to decision" in patients deteriorating rapidly before a full diagnostic and clinical evaluation can be made [4] . It is regarded as a class IIb recommendation with a level of evidence C. If the underlying disease which leads to ECMO implantation is of a potentially reversible cause, such as viral myocarditis, or a surgically correctable condition (e.g. acute interventricular septal rupture), the guidelines upgrade ECMO therapy to a class IIa recommendation, still with a level of evidence C.
Technical aspects: ECMO mode and configuration
The indication for ECMO determines the ECMO mode and configuration. While in respiratory failure, ECMO is implanted as a veno-venous circuit, cardiogenic shock requires ECMO in a veno-arterial configuration.
For venous drainage, a cannula is inserted into the right atrium through puncture of the common femoral vein (CFV). The right CFV is preferred since advancement of the cannula might be easier on the right side than the left side as a result of the bent course of the to control the arm perfusion. In exceptional cases, central ECMO via sternotomy with cannulation of the right atrium and ascending aorta might be required, such a s in c ase of refractory pulmonary oedema caused by a very low ejection fraction and the absence of left ventricular drainage, or postcardiotomy refractory cardiogenic shock. The technique described here is the preferred technique in our centre, it is based on available evidence and current practice, but some variations may be seen among implanting centres, including high-volume centres.
Outcome

Early survival
The outcome after ECMO therapy for cardiogenic shock is associated with low survival rates. But taking into account that, without ECMO, survival w ould b e extremely poor, the outcome may be r egarded as accept able. Several notable studies reported early survival of approximately 40% (fig. 2 ). The group in La Pitié, Paris, which is one of the most experienced centres in ECMO therapy, retrospectively examined 81 patients who were put on ECMO for cardiogenic shock due to medical, postcardiotomy or posttransplantation heart failure [5] . The analysis showed a 42% survival to h ospital discharge and a 38% survival a t 3 months. Early indepen dent predictors of death in the [6] . The availability of a reliable score is a serious concern of each centre offering ECMO therapy. Because of the tremendous costs for specialised personnel, ICU may be explained by the fact that 10 of the 20 studies included only patients with cardiogenic shock due to postcardiotomy syndrome, which is known to be associated with poor survival [3] . For all these reasons, the meta-analysis of Xie et al. [7] currently represents the best overview on early outcomes following ECMO for refractory cardiogenic shock, keeping in mind that large randomised studies have not been performed so far and, thus, at the moment pooled analysis represents t he b est available method f or evaluating ECMO [7] .
ELSO = Extracorporeal Life Support Organisation
Long-term results
Long-term results following ECMO for refractory cardiogenic shock are reported scarcely in the literature.
In the meta-analysis by Xie et al. [7] , the estimated 3-year survival was 42.7%, which was rather comparable to the survival to discharge, indicating that mortality was low once patients survived the initial hospitalisation for cardiogenic shock with subsequent ECMO therapy [7] . This has also been described in two other studies by Wu et al. [10] and Lidén et al. [11] . They reported 88% 3-year and 100% 5-year survival, respectively, of those patients who survived until hospital discharge following ECMO f or nonpostcardiotomy cardio genic shock or cardiac arrest [10, 11] . This corresponded with an overall 47% 3-year and a 63% 5-year survival, respectively. The C leveland C linic group reported much lower 3-year and 5-year survival rates of 26% and 24%, respectively [12] . This is explained by the fact that 53% of the 202 patients examined received the ECMO for postcardiotomy cardiogenic shock which is, as mentioned above, associated with poor outcome [3, 12] . Patients who receive the ECMO for cardiogenic shock due to acute myocardial infarction seem to do better than patients in cardiogenic shock because of acute decompensating chronic cardiomyopathy [13] . cal limit, leg ischaemia develops, which may require fasciotomy and, in some cases, amputation. Lower limb ischaemia has been reported to occur in 10-20% of patients [5, 7, 9, 12] . As a consequence, in 2-10% of patients a fasciotomy is needed, and in 2-5% of patients an amputation is performed [7, 9, 12] . To prevent such complications, which may be life-determining, the current state of the art is to place a distal perfusion limb into the SFA at the time of ECMO implantation.
Bleeding
Bleeding complications are triggered by the disseminated intravascular coagulation disorder, which is frequently associated with cardiogenic shock, insufficient production of coagulation factors resulting from liver failure, thrombocytopenia and the need for anticoagulation on ECMO. Major bleeding is reported to occur in 26-41% of patients [5, 7, 9] . Bleeding at the peripheral implantation site is described in 32% of patients [5] .
Neurology
Neurological complications include ischaemic stroke, cerebral bleeding, diffuse anoxic and metabolic brain injury and brain death. They may result from insufficient cerebral perfusion in cardiogenic shock or cardiac arrest before ECMO implantation, or develop under ECMO therapy caused by the complex coagulation disorder following cardiogenic shock. Two large metaanalyses reported the cumulative rate of all neurological complications to be at 13% [7, 9] , another singlecentre study described neurological events in 33% of patients [12] . In particular, ischaemic or haemorrhagic stroke is experienced by 6-8% of patients [7, 9] . high as 47-55% [ 7, 9 ] . Renal replacement therapy is required in 40-46% of all ECMO patients [9, 12, 13] .
Infection
Concluding comment
The fact that cardiogenic shock is not just a compro- interval has been shown to be a risk factor for mortality [5, 11] . This was most clearly shown in the extreme case scenario of the cardiogenic shock spectrum, namely ongoing CPR treated with ECMO (ECPR) [23] . Rapid implantation of ECMO is required to keep the period of low output as short as possible and to break the vicious cycle of inflammation early in its evolution. This, however, implies organisational and structural challenges, including mobile ECMO teams. The significant complication rates of ECMO therapy have to be incorporated into the risk-benefit analysis before treatment is initiat ed [7] . In patients with unclear neurological status, e.g., following unwitnessed out-of-hospital arrest, or with advanced end-organ failure and metabolic derangement, ECMO therapy may be denied since ethical and economical aspects argue against application of ECMO in patients with anticipated poor outcome.
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Summary
Sudden cardiac death (SCD) during sport is frequently the first and the last manifestation of an unrecognised, underlying, often asymptomatic heart disease. Athletes are seen as one of the healthiest segments of the population. SCD in an athlete is always shocking and profoundly affects the communities where it occurs. As a result of the considerable media attention that often accompanies SCD in an athlete, it has been suggested that its prevalence is overestimated. However, in reality the incidence may still be higher than we think as SCD events occurring during recreational-leisure sports may be underreported. An overall incidence of 1:50 000 athletes per year is a reasonable estimate based on available retrospective cohort studies and prospective observational or cross-sectional studies with male black basketball athletes being at higher risk (1:11 000 athletes per year).
Overall the health benefits of regular exercise heavily outweigh the risks of SCD in young and in older athletes, especially in those who train appropriately. This is "the paradox of sports": physicians are faced with the challenge of providing a sensible strategy for the prevention of SCD while simul taneously reaffirming that the benefits of regular exercise far outweigh potential risks. Considering the potentially increased, albeit small, risk of cardiac events and SCD during physical activity (PA), it is prudent to establish practical and pragmatic algorithms for the cardiovascular evaluation of young and of middle-aged / senior individuals before engaging in regular PA.
However, there is disagreement on how to implement an effective preparticipation screening strategy of SCD prevention in athletes, which is, at the same time, cost-effective. At present there is a broad range of screening recommendations, which vary from country to country.
In this brief review, we summarise the current state of knowledge in this area with respect to epidemiology, mechanisms, approaches to risk stratification based on existing scientific evidence and on expert documents.
Screening for SCD prevention in athletes by cardiology/sport physicians in
Switzerland will then be discussed.
Key words: sudden death prevention; athletes; sports; cardiac arrest
Epidemiology
Sudden cardiac death (SCD) in athletes is a rare event (1-2 / 100 000 / year) [1, 2] , with an incidence that varies depending on age, sex and intensity of sports activity.
The true incidence of SCD in athletes is widely debated.
Differences in current estimates of the incidence are largely due to differing methodology and heterogeneous population comparisons. S everal f actors a ffect case identification including the definition of an athlete, methods of data acquisition, too broad age ranges of the population, poorly defined examined population, SCD only during sport or at any time, lack of mandatory reporting requirements, inclusion or not of sudden cardiac arrest (SCA) survivors and absence of standardised autopsy protocols [1] .
In well-defined age subgroups, such as athletes aged 14-18 years, estimates of SCD/SCA annual incidence range from 1:50 000 to 1:80 000. High-risk subgroups identified include men (1:41 000) and male basketball athletes (1:33 000) [2] . Estimate of the SCD/SCA annual rate for athletes aged 17-24 years is 1:43 000 overall, with high-risk subgroups identified as men (1:33 000), African-Americans (1:18 000), m ale black basketball athletes (1:11 000) and Division I male black basketball athletes (1:3000) [3] . While athletes aged between 12 and 35 years present an estimated incidence of SCD of 1:47 000 [4] , in athletes aged 36-49 years estimates of SCD incidence reach 1:15 000 for competitive sports and 1:34 000 for noncompetitive sports [5] . Furthermore, SCD may be higher in some athletes (male, black, basketball player).
List of abbreviations:
CAD: coronary artery disease 
Classification of sports activities
Physical activity (PA) is defined as any bodily movement produced by skeletal muscles that results in energy expenditure beyond resting metabolism. The volume of PA (i.e., total energy expended) is expressed in metabolic equivalents or METS. One MET equals the resting metabolic rate of 3.5 ml O2/kg/min. The total volume of habitual PA level (volume = intensity × duration = METS × duration or MET-h/week) is a marker to discriminate low, moderate and high intensity activity.
According to these considerations, sports activities can be classified according to the type and intensity of exercise performed [6] . There are two broad types of exercise, dynamic (isotonic) and static (isometric), on the basis of the mechanical action of the muscles involved. 
Classification of athletes
It is important to differentiate between young and middle-age/senior individuals engaged in PA. To comply with the majority of cardiovascular literature, we are using the cut-off point of 35 years [10] . The incidence rate of SCD in sports is 4-5 times higher in older age groups (>35 years, e.g., master athletes) compared with athletes of a younger age (≤35 years) [11] . Athletes should be defined according to the type, frequency, dura tion and intensity of sport participation and categorised into "competitive" or "recreational" [12] . Com- Recreational sports do not necessarily require systematic training or the pursuit of excellence, nor do they convey the same pressure to prevail against others [12] .
Based on the above-mentioned description, we aim to divide athletes into:
1. Young athletes <35 years;
2. Middle-aged/older athletes ≥35 years.
And then stratified based on type, frequency, duration and intensity of sport activities: 
Cause and pathogenesis of sudden death during sports
The well-known beneficial effects of aerobic exercise [13, 14] are partly mediated through modification of several risk factors for coronary artery disease, including components of the metabolic syndrome and effects on endothelial dysfunction and blood coagulation [15] .
During sport activities, depending on the type of exer- The lack of prospective data validating the use of the 12-lead ECG to prevent SCD in sports has, however, lim- letes without compromising sensitivity [36] . Therefore, interpretation of the 12-lead ECG according to the most recent criteria has become highly sensitive (approximately 94%) and specific (94-96%). 
Preparticipation screening strategy
Assessment of risk profile for coronary artery disease
Where do we stand in Switzerland?
Since sport-associated SCD/SCA shows regional differences and varies widely with respect to underlying heart disease, sport, ethnicity and gender, national study / registers of SCD/SCA are necessary.
In Switzerland, a retrospective analysis that concerned only German-speaking cantons provided valuable insight into the epidemiology of SCD in our country. In this study, the incidence of leisure sports-associated SCD in athletes from 10 to 39 years was as low as 0.21 / 100 000 athletes per y ear, and competitive s portsassociated SCD was 0.57 / 100 000 athletes per year [38] .
As stated by the authors, because of its retrospective nature and because there was no standardised protocol for auto psy, some forms of cardiac arrest may have been misclassified. Nevertheless i nteresting, t he above-mentioned study showed that coronary artery Based on the study of Notz, Lüscher and Schmied [41] only 9% of the Swiss athletes (aged 13-35) had undergone preparticipation screening in their sports career previously and only 47% of the athletes were willing to undergo a preparticipation screening. Therefore, adherence to these screening initiatives also appears to be an important issue.
As far as costs are concerned, in Switzerland the federal law on prevention and health promotion regulates the introduction of management tools and coordination, as well as financing. As there is no clear law on the financ ing of prevention, in principle, the costs must be supported by the sport organism or by individual ath- These studies state that: 1) cardiovascular preparticipation examination with an ECG recording in young athletes and cardiovascular evaluation in middle-aged individuals engaged in high-intensity sports following the EACPR protocol is feasible in Switzerland at reasonable cost; 2) using modern and selective criteria for interpreting the ECG (developed for young athletes), the rate of abnormal ECGs is low even in the middle-aged group; 3) the ECG plays a key role in detecting serious cardiac disease. Therefore, according to the above-mentioned studies, the cost of pre participation screening in Switzerland seems reason able.
Reccommendations for preparticipation screening in Switzerland
The aim of preparticipation screening is to identify athletes with previously undetected, asymptomatic underlying heart or vascular disease in order to prevent SCD/SCA during sports [10, 29] . Given the impor- Considering what has been discussed above, taking into account the consensus statement of sports cardiology section of ESC, the "2011 AHA/ACC scientific statement on ECG screening", the incidence on SCD in Switzerland, and the studies carried out on athletes in Switzerland with implications for workload, yield and economic cost, for the Swiss reality, the following specific recommendations for a screening protocol could be proposed: 
If high risk then
-maximal exercise testing.
If negative → eligible for high-intensity activity;
if positive then further examinations to confirm or exclude an underlying cardiac disease, according to the recommendations for evaluation of athletes with cardiovascular abnormalities [25, 45] .
Conclusion
Although the risk of SCD/SCA among athletes is reported to be rather low across studies, this risk is likely to be underestimated because it is based on retrospective data. In order to obtain accurate data on SCD in athletes, a prospective, complete, mandatory reporting system of all cardiac arrest events is necessary with a reliable population of referral as the denominator. Healthcare systems have a responsibility to recommend increased PA by minimising risks and maximising benefits. Keeping in mind that the primary aim of the screening programme is to save athletes' lives rather than money, the economic concern is always delicate. However, as we have seen, the costs for the baseline evaluation as well as for the additional second-line cardiac examinations seem reasonable. Finally, as cardiovascular screening will never be able to identify all athletes at risk, for secondary prevention, adequate preparation is vital in case of a potentially fat al event at the sporting arena / facility.
Disclosure statement
References
The full list of references is included in the online version of the article at www.cardiovascmed.ch. MFET repair is a promising approach for the treatment of a covered rupture or complicated type B aortic dissection combined with ascending aortic dilatation.
Disclosure statement
No financial support and no other potential conflict of interest relevant to this article was reported. 
Presentation of the case
How did I treat this patient?
A 7-French XB3.5 guide catheter (Cordis, NJ, USA) was sited from the right femoral artery. The eccentricity of the in-stent restenosis within the LAD was considered We therefore opted to undertake plaque modification using rotational atherectomy (RA) as our initial strategy, prior to wiring the diagonal and thereby also preserving carina position. An alternative strategy to be considered is elective RA, which may debulk the plaque in a more controlled manner and can help preserve side-branch entry [5] .
RA was developed in the early 1980s as a strategy to debulk and modify coronary plaque disease, particularly in the presence of extensive calcification. RA relies upon the differential properties of the various components of coronary plaque disease, resulting in "cutting" of the harder plaque components (e.g., calcium), whilst leaving the elastic vessel wall largely unharmed. Although useful for this purpose, RA fell out of favour as the "over-the-wire" technique requires two experienced operators, and clinical trials (largely in the bare metal stenting era) failed to demonstrate improvements in either mortality or morbidity [6] .
However, recently RA has again emerged as an important ancillary tool to aid stent delivery into complex anatomy as marked improvements in stent technology have allowed complex PCI such as in the present case to be undertaken with good outcomes.
Regarding in-stent r estenosis, u sual p ractice is t o undertake predilatation with n oncompliant a nd/or cutting balloons and to ensure adequate expansion prior to further stent (or drug-eluting balloon) deployment. This is important as failure to adequately expand during the predilatation stage is strongly pre dictive of recurrent in-stent restenosis [7] . RA has previously been undertaken through previously deployed stents without complication and may be useful in cases where aggressive predilation has failed to achieve adequate expansion. However, as yet RA has not been demonstrated to reduce likelihood of recurrent in-stent restenosis [8] .
Therefore the utility of routine RA in the context of instent restenosis is uncertain, particularly as such disease is relatively elastic and may not always respond to RA in the same way as calcific atheroma. 
Conclusion
RA can be used effectively to modify in-stent restenosis and safely permit wire access in a difficult-to-wire side-branch.
Disclosure statement
